H3-DYNAMICS
The future of hydrogen aviation powered by H3 Dynamics’ distributed hydrogen propulsion nacelles has taken flight for the very first time in France.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221121006001/en/
H3 Dynamics distributed hydrogen electric nacelles proven on first flight (Photo: Business Wire)
Following the announcement of its hydrogen aviation concept back in 2018, H3 Dynamics managed to become a topic at an Oval Office press conference on the very next day, and started what is now a global hydrogen aviation movement.
In November 2021, H3 Dynamics completed its first working hydrogen propulsion nacelle prototype. In July 2022, the first distributed pod system took to the skies on a scaled-down aircraft at “Hub Drones - Systematic” airfield near Paris. The hydrogen flight received clearance from the French civil air authorities (DGAC).
H3 Dynamics’ self-contained nacelle approach addresses technical, safety and cost challenges hydrogen aircraft developers could face at some point in the future. It achieves this by placing hydrogen and smaller fuel cells across a series of collaborative propulsion nacelles under the wings. A new 2022 study forecasts the global thrust nacelle market to reach $7 Billion by 2030 highlights H3 Dynamics’ hydrogen solution as a key new opportunity in the sector.
Other, higher-visibility hydrogen aircraft proponents will fly larger size aircraft much sooner – but they will do so by converting existing aircraft using fuel cells sourced from the automotive world – and storing large amounts of gas or liquid hydrogen inside the main fuselage.
“Not only is safety our first priority, but we don’t want hydrogen competing for revenue-generating airfreight and passenger space,” said Taras Wankewycz, Founder/CEO of H3 Dynamics. Distributing small systems solves technical headaches, such as thermal management, and increases safety through multiple redundancy.
H3 Dynamics’ 25kg test aircraft is already a breakthrough - with an electric flight range of up to 900km on liquid hydrogen, or 350km with pressurized hydrogen. Its externalized nacelle design also frees up 30L of fuselage volume with no hydrogen nor any powertrain elements inside. H3 Dynamics’ hydrogen propulsion nacelles could potentially become a “snap-on” retrofit for battery-powered unmanned eVTOL or fixed wing cargo drones.
Preparing for the arrival of much longer duration unmanned hydrogen flights - H3 Dynamics started to work on airspace safety with world-leading air traffic control companies. It has been building experience with high-volume enterprise data services being deployed in smart cities such as Singapore, and gradually coupling these with drone-agnostic charging stations.
By starting at the lower-end boundary of regulatory and certification efforts, H3 Dynamics doesn’t need to wait until 2035 to begin its commercial journey. “We all need to learn today with small commercial applications and gradually increase aircraft size over time together with all stakeholders – most importantly, the regulators.”
Now H3 Dynamics is already preparing its next steps.
It is exploring liquid hydrogen integration as part of a joint-development with ISAE-SUPAERO in Toulouse launched in 2019. The objective is a historical and symbolic Atlantic crossing on hydrogen electric propulsion in the coming two years.
And with airfield experiments feeding its digital twin capability for hydrogen aircraft design, H3 Dynamics is now working on a next generation platform powered by 6 independent hydrogen-electric nacelle systems. The aircraft will feature fast-refueling and will be used as a test bed for H3 Dynamics hydrogen-electric propulsion technology moving forward.
About H3 Dynamics: www.h3dynamics.com
H3 Dynamics is on a long-term mission to decarbonize aviation with a unique technology solution around distributed hydrogen-electric propulsion, as well as ground refueling solutions. While the commercial opportunities around passenger-scale hydrogen aviation continue to mature, the company is implementing an incremental product and services roadmap that solves safety, technical, regulatory challenges starting small and simple, adding scale and complexity over time. The company currently has 95 employees and serves clients globally from its 3 regional headquarters in Toulouse, Austin and Singapore. H3 Dynamics is member of the Alliance for Zero Emission Aviation under the European Commission, the Lufthansa Cleantech Hub, Paris Advanced Air Mobility Alliance, and Aerospace Valley in Toulouse.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221121006001/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom